COX-2 selective inhibitors cardiac toxicity: Getting to the heart of the matter

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 7, Issue 3, 2004, Pages 332-336

  Davies, Neal M ^a   Jamali, Fakhreddin ^b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BENOXAPROFEN; BROMFENAC; CARPROFEN; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DRUG METABOLITE; ETODOLAC; ETORICOXIB; IBUPROFEN; INDOMETACIN; LUMIRACOXIB; MELOXICAM; MOBICOX; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PIRPROFEN; PLACEBO; ROFECOXIB; VALDECOXIB;

ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG INDICATION; DRUG METABOLISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG USE; DRUG WITHDRAWAL; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HEART DEATH; HEART INFARCTION; HOMEOSTASIS; HUMAN; LOW DRUG DOSE; NONHUMAN; STOMACH HEMORRHAGE; STOMACH ULCER;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; INCIDENCE; LACTONES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONES;

EID: 16244365087     PISSN: 14821826     EISSN: 14821826     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343:1520-1528, 2000.
2. Reicin AS, Shapiro D, Sperling RS. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol 89: 204-209, 2002.
3. Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 104:2280-8, 2001.
4. Weir MR, Sperling RS, Reicin A, Gertz BJ. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J 146:591-604, 2003.
5. http://www.dirc-canada.org/nddn/DIRC%20Care%20Advisory%20Vioxx.pdf
6. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38:97-120, 1998.
7. Khan KN, Paulson SK, Verburg KM, Lefkowith JB, Maziasz TJ. Pharmacology of Cyclooxygenase-2 inhibition in the kidney. Kidney Int 61:1210-1219,2002.
8. Hensley, Scott: Pfizer to Test Celebrex as Heart Aid. http://www.wsj.com
9. Mayo PR, Skeith K, Russell AS, Jamali F Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. Br J Clin Pharmacol 50:605-613, 2000.
10. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study. J Am Med Asscc 284: 1247-1255, 2000.
11. Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 38:225-242, 2000.
12. Davies NM, Teng XW, Skjodt NM. Pharmacokinetics of rofecoxib: a specific cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 42:545-556,2003.